Log In

 

Company Name : Datar Cancer Genetics Limited

Thursday, October 12, 2017 7:17PM IST (1:47PM GMT)

Datar Cancer Genetics Launches Breakthrough Blood Test for Early Detection of 15 Cancers


The Early Warning Test is a blood test that can accurately detect the presence of malignancy in the human body by characterizing nano particles called exosomes which are released by cancer cells


Mumbai, Maharashtra, India

Early detection of cancer has been the Holy Grail for scientists all over the world. Late stage detection is one of the primary reasons for death in cancer patients. Datar Cancer Genetics has developed a simple non-invasive blood test to detect the presence of cancer in seemingly healthy persons, using advanced molecular analysis of nano particles released by cancer cells. The pattern of various genes expressed in the cancer cells is captured in these nano particles known as ‘exosomes’. This breakthrough technology has been developed in India using latest Artificial Intelligence techniques and is based upon the study of more than 3000 samples from cancer patients. The test analyzes all 22000 protein-coding genes in the human genome and is able to detect the presence of breast, cervices, ovary, endometrium, lung, colon, sarcoma and many more cancers with an accuracy of better than 95%.
 
The test is available in all cities in India and the company has made arrangements for collection of the blood sample from home/office. The test can be availed by any person above the age of 35 and who has no previous known history of having any cancer.
 
Speaking at the launch, Dr. D. Akolkar, Director of Research and Innovation said that it is a proud moment not only for the company but also for the country as the test has given a pole vault position in cancer research. He also said that the company, working with a frugal budget has beaten the worldwide competition which is funded with billions of dollars and government support. Dr. Akolkar said that research in cancer is an imperative of recent times and Datar Cancer Genetics has committed significant resources not only for early detection of cancer but towards making the treatment of stage IV patients more effective and possibly curative.
 
Datar Cancer Genetics Limited has been accredited by NABL and TUV for ISO 9001:2008 for medical reporting and has a modern, differential pressure molecular oncology facility in Nasik, India. With the launch of the Early Warning Test, the company has entered into a USD 20 billion market worldwide. 


Click here for Media Contact Details

D. Umapathi, Senior Manager , Datar Cancer Genetics Limited, +91-9822081777, +91 (253) 6604828, umapathi@datarpgx.com


More News from Datar Cancer Genetics Limited

12/01/2018 3:24PM

Datar Cancer Genetics Limited is now CAP Accredited

Datar Cancer Genetics Limited, a leading molecular and genetic analysis company has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP), post a recent on-site ...

Similar News

20/02/2018 10:50PM

TVGE International Extends Global Reach with Satellite and Online Distribution via SES and MX1

TVGE International, Equatorial Guinea’s governmental channel, is partnering with SES and MX1 to deliver its content worldwide on both linear and non-linear platforms. TVGE International is a free-to-air, ...

No Image

20/02/2018 10:30PM

Entersekt Partners With ForgeRock

Entersekt, a pioneer in mobile-first authentication and e-commerce enablement, announced today that it has joined the ForgeRock Trust Network as a principal technology partner. ForgeRock is a leading provider of ...

News Summary

Early detection of cancer has been the Holy Grail for scientists all over the world. Late stage detection is one of the primary reasons for death in cancer patients. Datar Cancer Genetics has developed a simple non-invasive blood test to detect the presence of cancer in seemingly healthy persons, using advanced molecular analysis of nano particles released by cancer cells.